A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Parabilis Medicines, Inc.
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Merck Sharp & Dohme LLC
Qilu Pharmaceutical Co., Ltd.
Eli Lilly and Company
Bio-Cancer Treatment International Limited
Traws Pharma, Inc.
Sanofi
Sanofi
Sanofi
Sanofi